NESS002ie

A new fluorinated thiol endopeptidase inhibitor with antinociceptive activity in an animal model of persistent pain

Simone Tambaro, Roberta Reali, Alessandro Volonterio, Matteo Zanda, Francesca Olimpieri, Gerard Aime Pinna, Paolo Lazzari

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

For the past few decades membrane zinc metallopeptidases have been identified as important therapeutic targets in the control of pain. In particular, neutral endopeptidase (NEP) has been shown to play critical roles in the metabolism of the endogenous peptides Met- and Leu-enkephalins. In this study, we have evaluated the activity of a new fluorinated peptidase inhibitor NESS002ie in both in vitro and in vivo assays. NESS002ie has been compared to the peptidomimetic compound thiorphan and the previously reported NEP selective thiol inhibitor C20. The metallopeptidases inhibitory activity of NESS002ie was tested in vitro using a highly, sensitive, continuous, fluorometric, enzyme assay. Also, the analgesic propriety of NESS002ie, thiorphan and C20 have been evaluated in vivo, by intraplantar, intravenous and intrathecal administration, through nociception assays based on formalin test in mice. Metallopeptidases assays have shown an inhibitory potency of NESS002ie in the nanomolar range for NEP and angiotensin-converting enzyme (ACE). The new fluorinated inhibitor showed higher analgesic activity and bioavailability compared to thiorphan and C20 when administered by both intravenous and intrathecal injections. More significantly, intrathecal injection of NESS002ie reduced both the first and the second phases of the formalin biphasic pain response. In addition, naltrindole and naloxone reversed the analgesic effect of NESS002ie with a diverse profile. This study shows an improvement in relief of inflammation and pain, in vivo, using NESS002ie compared to reference compounds thiorphan and C20. This significant effect could be due to the replacement of isobutyl chain of the thiol C20 with the trifluoromethyl group.
Original languageEnglish
Pages (from-to)137-144
Number of pages8
JournalPharmacology, Biochemistry & Behavior
Volume110
DOIs
Publication statusPublished - Sep 2013

Fingerprint

Protease Inhibitors
Sulfhydryl Compounds
Animals
Animal Models
Thiorphan
Pain
Neprilysin
Assays
Metalloproteases
Analgesics
Spinal Injections
naltrindole
Formaldehyde
Peptidomimetics
Leucine Enkephalin
Methionine Enkephalin
Nociception
NESS002ie
Enzyme Assays
Peptidyl-Dipeptidase A

Keywords

  • thiorpan
  • enkephalinase inhibitor
  • neutral endopeptidase
  • angiotensin-converting enzyme
  • formalin test
  • inflammatory pain

Cite this

NESS002ie : A new fluorinated thiol endopeptidase inhibitor with antinociceptive activity in an animal model of persistent pain. / Tambaro, Simone; Reali, Roberta; Volonterio, Alessandro; Zanda, Matteo; Olimpieri, Francesca; Pinna, Gerard Aime; Lazzari, Paolo.

In: Pharmacology, Biochemistry & Behavior, Vol. 110, 09.2013, p. 137-144.

Research output: Contribution to journalArticle

Tambaro, Simone ; Reali, Roberta ; Volonterio, Alessandro ; Zanda, Matteo ; Olimpieri, Francesca ; Pinna, Gerard Aime ; Lazzari, Paolo. / NESS002ie : A new fluorinated thiol endopeptidase inhibitor with antinociceptive activity in an animal model of persistent pain. In: Pharmacology, Biochemistry & Behavior. 2013 ; Vol. 110. pp. 137-144.
@article{3fe97580d86641bf8186aaa1a6cd139a,
title = "NESS002ie: A new fluorinated thiol endopeptidase inhibitor with antinociceptive activity in an animal model of persistent pain",
abstract = "For the past few decades membrane zinc metallopeptidases have been identified as important therapeutic targets in the control of pain. In particular, neutral endopeptidase (NEP) has been shown to play critical roles in the metabolism of the endogenous peptides Met- and Leu-enkephalins. In this study, we have evaluated the activity of a new fluorinated peptidase inhibitor NESS002ie in both in vitro and in vivo assays. NESS002ie has been compared to the peptidomimetic compound thiorphan and the previously reported NEP selective thiol inhibitor C20. The metallopeptidases inhibitory activity of NESS002ie was tested in vitro using a highly, sensitive, continuous, fluorometric, enzyme assay. Also, the analgesic propriety of NESS002ie, thiorphan and C20 have been evaluated in vivo, by intraplantar, intravenous and intrathecal administration, through nociception assays based on formalin test in mice. Metallopeptidases assays have shown an inhibitory potency of NESS002ie in the nanomolar range for NEP and angiotensin-converting enzyme (ACE). The new fluorinated inhibitor showed higher analgesic activity and bioavailability compared to thiorphan and C20 when administered by both intravenous and intrathecal injections. More significantly, intrathecal injection of NESS002ie reduced both the first and the second phases of the formalin biphasic pain response. In addition, naltrindole and naloxone reversed the analgesic effect of NESS002ie with a diverse profile. This study shows an improvement in relief of inflammation and pain, in vivo, using NESS002ie compared to reference compounds thiorphan and C20. This significant effect could be due to the replacement of isobutyl chain of the thiol C20 with the trifluoromethyl group.",
keywords = "thiorpan, enkephalinase inhibitor, neutral endopeptidase, angiotensin-converting enzyme, formalin test, inflammatory pain",
author = "Simone Tambaro and Roberta Reali and Alessandro Volonterio and Matteo Zanda and Francesca Olimpieri and Pinna, {Gerard Aime} and Paolo Lazzari",
year = "2013",
month = "9",
doi = "10.1016/j.pbb.2013.06.008",
language = "English",
volume = "110",
pages = "137--144",
journal = "Pharmacology, Biochemistry & Behavior",
issn = "0091-3057",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - NESS002ie

T2 - A new fluorinated thiol endopeptidase inhibitor with antinociceptive activity in an animal model of persistent pain

AU - Tambaro, Simone

AU - Reali, Roberta

AU - Volonterio, Alessandro

AU - Zanda, Matteo

AU - Olimpieri, Francesca

AU - Pinna, Gerard Aime

AU - Lazzari, Paolo

PY - 2013/9

Y1 - 2013/9

N2 - For the past few decades membrane zinc metallopeptidases have been identified as important therapeutic targets in the control of pain. In particular, neutral endopeptidase (NEP) has been shown to play critical roles in the metabolism of the endogenous peptides Met- and Leu-enkephalins. In this study, we have evaluated the activity of a new fluorinated peptidase inhibitor NESS002ie in both in vitro and in vivo assays. NESS002ie has been compared to the peptidomimetic compound thiorphan and the previously reported NEP selective thiol inhibitor C20. The metallopeptidases inhibitory activity of NESS002ie was tested in vitro using a highly, sensitive, continuous, fluorometric, enzyme assay. Also, the analgesic propriety of NESS002ie, thiorphan and C20 have been evaluated in vivo, by intraplantar, intravenous and intrathecal administration, through nociception assays based on formalin test in mice. Metallopeptidases assays have shown an inhibitory potency of NESS002ie in the nanomolar range for NEP and angiotensin-converting enzyme (ACE). The new fluorinated inhibitor showed higher analgesic activity and bioavailability compared to thiorphan and C20 when administered by both intravenous and intrathecal injections. More significantly, intrathecal injection of NESS002ie reduced both the first and the second phases of the formalin biphasic pain response. In addition, naltrindole and naloxone reversed the analgesic effect of NESS002ie with a diverse profile. This study shows an improvement in relief of inflammation and pain, in vivo, using NESS002ie compared to reference compounds thiorphan and C20. This significant effect could be due to the replacement of isobutyl chain of the thiol C20 with the trifluoromethyl group.

AB - For the past few decades membrane zinc metallopeptidases have been identified as important therapeutic targets in the control of pain. In particular, neutral endopeptidase (NEP) has been shown to play critical roles in the metabolism of the endogenous peptides Met- and Leu-enkephalins. In this study, we have evaluated the activity of a new fluorinated peptidase inhibitor NESS002ie in both in vitro and in vivo assays. NESS002ie has been compared to the peptidomimetic compound thiorphan and the previously reported NEP selective thiol inhibitor C20. The metallopeptidases inhibitory activity of NESS002ie was tested in vitro using a highly, sensitive, continuous, fluorometric, enzyme assay. Also, the analgesic propriety of NESS002ie, thiorphan and C20 have been evaluated in vivo, by intraplantar, intravenous and intrathecal administration, through nociception assays based on formalin test in mice. Metallopeptidases assays have shown an inhibitory potency of NESS002ie in the nanomolar range for NEP and angiotensin-converting enzyme (ACE). The new fluorinated inhibitor showed higher analgesic activity and bioavailability compared to thiorphan and C20 when administered by both intravenous and intrathecal injections. More significantly, intrathecal injection of NESS002ie reduced both the first and the second phases of the formalin biphasic pain response. In addition, naltrindole and naloxone reversed the analgesic effect of NESS002ie with a diverse profile. This study shows an improvement in relief of inflammation and pain, in vivo, using NESS002ie compared to reference compounds thiorphan and C20. This significant effect could be due to the replacement of isobutyl chain of the thiol C20 with the trifluoromethyl group.

KW - thiorpan

KW - enkephalinase inhibitor

KW - neutral endopeptidase

KW - angiotensin-converting enzyme

KW - formalin test

KW - inflammatory pain

U2 - 10.1016/j.pbb.2013.06.008

DO - 10.1016/j.pbb.2013.06.008

M3 - Article

VL - 110

SP - 137

EP - 144

JO - Pharmacology, Biochemistry & Behavior

JF - Pharmacology, Biochemistry & Behavior

SN - 0091-3057

ER -